AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
REDWOOD CITY, Calif., April 19, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective April 19, 2018, the compensation committee of the company’s board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the company’s common stock with a per share exercise price of $12.05, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
